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Cancer Epigenetic~ and its Clinical Applications 
Epigenetics is defined as 'somatically inheritable changes 
that are not accompanied by alterations in DNA sequence'. 
DNA methylation, histone modifications and non-coding 
RNAs are all epigenetic mechanisms. Epigenetic aberrations 
(or epimutations) have been found to be responsible for 
carcinogenesis. The research of these epimutations is providing 
a platform for their application in cancer diagnosis, prognosis 
and therapeutics. 
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What causes cancer? One of the most frequent answers to this 
question is that 'it's in our genes'. but what does that mean? 
The wealth of literature demonstrating that damaged genes 
are a cause of cancer is irrefutable. However, in recent years, a 
growing body of research has suggested that epigenetics also 
plays a critical role in this disease.1 
Historically, the word 'epigenetic' was used to describe 
the phenomenon of cell identity.2 Our bodies exhibit a great 
diversity in cell identity, with over 200 different cell types all 
depending on one genome. This variation is regulated by a 
system of biochemical alterations of DNA and histone proteins, 
which give DNA its structure. Together, these modifications are 
termed the epigenome. 
Epigenetic modifications include DNA methylation, histone 
modifications and RNA epigenetics. Epigenetic modifications 
have importance in gene transcription, but they do not actually 
modify the coding sequence of the gene itself. While these 
alterations are heritable, there is also the possibility of reversing 
them; a fact that has enabled the prospect of epigenetic 
therapy in cancer treatment. Indeed, epimutations have 
therefore been targeted for new drug innovations, and "turning 
back on" silenced genes represents a crucial advancement in 
treating different forms of cancer.3 
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DNA methylation 
DNA methylation is a type of epigenetic modification that 
has been extensively studied in mammals. In normal cells, it 
ensures the correct regulation of gene expression and stable 
gene silencing. DNA methylation is closely linked with histone 
modifications, and their interaction is fundamental in controlling 
genome functioning by altering chromatin architecture. 
Generally, the methylation pattern is maintained by DNA 
methyltransferases. In various cancer types, DNA methylation 
has been shown to silence a wide range of genes, with 
inactivation of cenain tumour-suppressor genes occurring as a 
consequence of hypermethylation within the promoter regions.• 
Histone modifications 
In normal cells, histone modifications systematically coordinate 
and oversee cellular processes such as DNA repair, DNA 
replication and gene transcription. In recent years, research 
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attention on histone modifications has intensified, leading to 
the detection and categorisation of many histone-modifying 
protein complexes and molecules. Changes in these complexes 
are thought to disturb the configuration and levels of histone 
marks, and so disrupt the regulation of chromatin-based 
processes, eventually resulting in oncogenic transformation and 
cancer development.5 
RNA epigenetics 
Several studies have shown that microRNAs (miRNAs) can also 
have clinical relevance as biomarkers to indicate the presence 
of a pathology and also the genetic link, progression or stage 
of the cancer.4 
It is known that epigenetic factors are involved in 
aberrations of the miRNome (that is, the complete set of 
miRNAs for a certain genome) which are seen in cancer. It is 
also known that a group of miRNAs known as epi-miRNAs can 
directly target effectors of the epigenetic machinery, including 
DNA methyltransferases, histone deacetylases (HDACs), and 
polycomb repressive complex genes. Epi-miRNAs can also 
indirectly affect the expression of tumour suppressor genes, 
whose expression is controlled by epigenetic factors. 
Such epigenetic-miRNA interact ion results in a new layer 
of complexity in gene regulation, opening up new avenues 
in the understanding of human cancerogenesis and in the 
achievement of new cancer treatments.' 
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In a race against precious time, epigenetic therapy emerged as 
a treatment option when it was discovered that the epigenetic 
alterations that occur in cancer are reversible in nature. In fact, 
one of the main aims of epigenetic therapy is to reverse the 
epigenetic modifications that occur in cancer, therefore leading 
to the restoration of a healthy and normal epigenome. In recent 
years, drug development on this front has focused on DNA 
methyltransferases, HDACs, histone acetyltransferase (HATs) 
and miRNA-based therapeutic strategies.8 
DNA methyltransferase inhibitors 
Drugs such as the DNA methyltransferase inhibitors azacitidine9 
and decitabine10 have, for instance, been found to target the 
inverted methylation pattern of cancer cells. It was shown that 
these hypomethylating agents not only inhibit all three types of 
DNA methyltransferases (DNMTl, DNMT3a, and DNMT3b), but 
they are also effective when used in low dosage. Indeed, both 
azacitidine and decitabine have been used in the treatment of 
patients with acute myeloid leukaemia, chronic myelomonocytic 
leukaemia and higher-risk myelodysplastic syndromes, who are 
unable to be considered for more intensive treatments such as 
induction chemotherapy or stem cell transplantation." 




In addition to DNA methyltransferase inhibitors, a few HDAC 
inhibitors have been approved by the FDA, including vorinostat, 
panobinostat and romidepsin. Besides the histone of interest, 
these HDAC inhibitors are known to alter the acetylation 
state of many proteins. Additional research at the molecular 
level of patient response is therefore needed to improve 
the effectiveness of these inhib itors as cancer treatment. 
Nonetheless, both vorinostat and romidepsin have been used 
in the treatment of cutaneous T<ell lymphoma.12. 13 Similarly, 
panobinostat has been used as a therapeutic option for 
multiple myeloma, although its use has been restricted due to 
its adverse event profile." 
HAT inhibitors 
HAT inhibitors are other pharmaceutical targets in cancer 
research. Lunasin, for example, is a soybean-derived 
polypeptide which has been found to bind to deacetylated 
histones competing with HATs, and in doing so, switching 
off transcription. Such an epigenetic mechanism therefore 
suggests that this polypeptide can affect regulatory pathways 
involving chromatin changes that could be important to 
carcinogenic pathways. Wan et al. (2017) argue that lunasin 
could therefore be effective against cancers that invo lve 
chromatin modifications.'~ 
Similarly, the natural product HAT inhibitors anacardic acid16 
and garcinol'7 have been shown to sensitise cancerous cells 
to irradiation. In mice, garcinol inhibited proliferation of breast 
cancer cells and also suppressed colon carcinogenesis.1S.•9 
Curcumin, which is another HAT inhibitor, is currently in clinical 
trials as a therapeutic agent and combination therapy, however 
its biological effect is not only due to its HAT inhibition.20 
miRNA-based therapeutic strategies 
Epigenetic therapies also include miRNA-based therapeutic 
strategies. In general, miRNAs are a feasible therapeutic tool 
because they can regulate key cellular processes by also 
simultaneously regulating several targets. Currently, there are 
two strategies for the treatment of cancer using RNAi-based 
therapy: (a) the 'sandwich RNAi inhibition' strategy and (b) the 
'multiplex RNAi inhibition' strategy.2 '.22 In the former strategy, 
multiple agents are used to target a specific molecular defect 
connected to cancer pathogenesis. In the latter strategy, on the 
other hand, it is the various molecular defects which accumulate 
in the multistep pathway of a specific cancer that are targeted. 
In murine models for example, Xue et al. (2014) found that 
delivery of miR-34a and K-ras siRNA into a lung cancer model 
resulted in significant tumour regression.23 Similarly, Yuan et 
al. (2014) fo und that siRNA-mediated inhibition o f KRAS, in 
addition to RAF or Pl3K combinations, could impair KRAS-
mutant colorectal cancer in xenograft models.2• 
In human studies, while some miRNA candidates have 
failed, others have shown potential. In the first human trial of 
its kind, a technology termed "TargomiR" exhibited promising 
results in patients with malignant pleural mesothelioma and 
non-small cell lung cancer.2S In this technology, miRNA mimics 
are delivered by targeted bacterial minicells. In addition, 
there is a new miRNA drug candidate called RGLS5579 that 
targets miR-10b which has potential in patients diagnosed 
with glioblastoma multiforme - one of the most aggressive 
forms of brain cancer.2"'7 In glioblastomas, miR· 1 Ob is over-
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expressed and is an oncogenic m iRNA. Overall, these studies 
suggest a feasible future for miRNA drugs in cancers with no 
effective treatments. 
It is dear that epigenetic therapeutics has a promising future for 
cancer treatment. Nevertheless, we still need to fully comprehend 
the complex system of interactions between the human genome 
and epigenome, transcriptome and proteome. Looking into the 
future, if the potential for epigenetic therapy is fulfilled, it will 
definitely open an exciting new avenue for personalised cancer 
treatment medicines. 
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